Ondansetron in the treatment of nausea and vomiting induced by chemotherapy

One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting. The study had two groups of patients, one receiving...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anti-cancer drugs 1993-12, Vol.4 Suppl 2 (Supplement 2), p.23-27
Hauptverfasser: Ribiero, M Manso, de Faria, L, dos Reis, F, Fráguas, A, de Matos, E, Uva, S, Ribeiro, I, Brandão, A, Ribeiro, M, Silva, A Sousa e, de Oliveira, E, Albuquerque, J, Gil, N, de Carvalho, V, de Castro, T, Justiça, B, Ribeiro, A Pinto, Moura, P Garça, Ribeiro, M Mendes, Castro, I, Andrade, J, Pinguinha, A, Rodrigues, M Teresa, Horta, L, Inock, A, Teixeira, C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting. The study had two groups of patients, one receiving cisplatin-containing regimens (Group A) and the other, non-cisplatin-containing regimens (Group B). There were 51 patients recruited to Group A. Ondansetron was given to these patients at a dose of 8 mg intravenously 15 min before chemotherapy, followed by an intravenous infusion for 24 h (1 mg/h), or 8 mg intravenously 4 and 8 h after the start of cisplatin, followed by 8 mg orally three times/day for 5 days. Ninety-four patients were recruited to Group Bthese patients received ondansetron at a dose of 8 mg intravenously immediately before chemotherapy or 8 mg orally 1–2 h prior to it, and 8 mg orally three times/day for 3–5 days. For acute emesis (first 24 h), complete control was achieved in 79.5% of Group A patients and in 78.1% of Group B. For delayed emesis (days 2–5), 79.7% of Group A patients and 84.6% of Group B were completely protected during the entire study period. Nausea was also well controlled with ondansetron; 83.2% (Group A) and 86.5% (Group B) reported only mild nausea or no nausea at all. Ondansetron was effective in the control of both cisplatin- and non-cisplatin-induced emesis and well tolerated without any serious drug-related adverse events.
ISSN:0959-4973
1473-5741
DOI:10.1097/00001813-199312002-00004